Leerink Partners将AN2 Therapeutics评级上调至“跑赢大盘”,目标价大幅调升至9美元

美股速递
May 14

投资机构Leerink Partners宣布,将生物制药公司AN2 Therapeutics, Inc.的股票评级从“与大盘持平”上调至“跑赢大盘”。与此同时,该机构将其目标股价进行了显著上调,从原先的1美元大幅提升至9美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10